202 related articles for article (PubMed ID: 2182519)
21. Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice.
Titus JA; Garrido MA; Hecht TT; Winkler DF; Wunderlich JR; Segal DM
J Immunol; 1987 Jun; 138(11):4018-22. PubMed ID: 3108382
[TBL] [Abstract][Full Text] [Related]
22. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
[No Abstract] [Full Text] [Related]
23. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice.
Ortaldo JR; Porter HR; Miller P; Stevenson HC; Ozols RF; Hamilton TC
Cancer Res; 1986 Sep; 46(9):4414-9. PubMed ID: 3089592
[TBL] [Abstract][Full Text] [Related]
24. [Identification and characterization of effector lymphocytes lysing autologous tumor cells].
Kumagai K; Fujii M; Abo T; Sawada H; Kato M; Itoh K; Satoh T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1462-8. PubMed ID: 2658829
[TBL] [Abstract][Full Text] [Related]
25. Human CD3 gamma delta + activated lymphocytes exhibit killer activity in vitro against autologous leukemic cells.
Bensussan A; Lagabrielle JF; Castaigne S; Boisson N; Miclea JM; Benbunan M; Degos L
Nouv Rev Fr Hematol (1978); 1989; 31(2):129-32. PubMed ID: 2528119
[TBL] [Abstract][Full Text] [Related]
26. Studies on lymphokine activated killer cells in the rat: analysis of precursor and effector cell phenotype and relationship to natural killer cells.
Hiserodt JC; Vujanovic NL; Reynolds CW; Herberman RB; Cramer DV
Prog Clin Biol Res; 1987; 244():137-46. PubMed ID: 2958869
[No Abstract] [Full Text] [Related]
27. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
28. Induction of NK-like activity in T cells by IL-2/anti-CD3 is linked to expression of a new antitumour receptor with specificity for acetylated mannose.
Zollner TM; Zhu HG; Anderer FA
Anticancer Res; 1993; 13(4):923-30. PubMed ID: 8352560
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic aspects of successful immunotherapy of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2.
Mulé JJ; Rosenberg SA
Prog Clin Biol Res; 1987; 244():79-91. PubMed ID: 3310006
[No Abstract] [Full Text] [Related]
30. In vitro generation of therapeutic noncytolytic T-cells by soluble polyoma TAA and Il-2.
Ochalek T; von Kleist S
Anticancer Res; 1993; 13(4):1171-7. PubMed ID: 8394674
[TBL] [Abstract][Full Text] [Related]
31. Natural killer cells.
Herberman RB
Prog Clin Biol Res; 1989; 288():161-7. PubMed ID: 2470107
[No Abstract] [Full Text] [Related]
32. [Fundamental and clinical aspects of adoptive immunotherapy with tumor-infiltrating lymphocytes].
Yahata G; Okada Y; Honda S; Tanaka K; Tokunaga A; Takahashi T; Seidou T; Takeuchi S
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1474-82. PubMed ID: 2471459
[TBL] [Abstract][Full Text] [Related]
33. [Subpopulations of human T-lymphocytes and their suppressor functions].
Brondz BD
Ter Arkh; 1980; 52(9):120-32. PubMed ID: 6449090
[No Abstract] [Full Text] [Related]
34. [Effects of prostaglandins on the activity of natural killer cells during tumor growth].
Shparyk IaV; Bilynskiĭ BT; Iuk TL
Eksp Onkol; 1990; 12(3):10-4. PubMed ID: 2188828
[TBL] [Abstract][Full Text] [Related]
35. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
Shu S; Chou T; Rosenberg SA
Cancer Res; 1987 Mar; 47(5):1354-60. PubMed ID: 3102046
[TBL] [Abstract][Full Text] [Related]
36. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
37. [A new approach to immunotherapy of cancer based on autologous T-lymphocytes].
Dosne Pasqualini C; Laguens RP
Medicina (B Aires); 1987; 47(3):307-12. PubMed ID: 3326997
[No Abstract] [Full Text] [Related]
38. Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients.
Blanchard DK; Kavanagh JJ; Sinkovics JG; Cavanagh D; Hewitt SM; Djeu JY
Cancer Res; 1988 Nov; 48(22):6321-7. PubMed ID: 2972357
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice.
Sun T; Kim TS; Waltz MR; Cohen EP
Cancer Gene Ther; 1995 Sep; 2(3):183-90. PubMed ID: 8528961
[TBL] [Abstract][Full Text] [Related]
40. Motility and tumoricidal activity of interleukin-2-stimulated lymphocytes.
Ratner S; Heppner GH
Cancer Res; 1988 Jun; 48(12):3374-80. PubMed ID: 2453269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
